Oxidation in rheumatoid arthritis

Arthritis Research and Therapy

Volumn 6, Issue 6, 2004, Pages 265-278

  Hitchon, C A ^a   El Gabalawy, Hani S ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Hypoxia; Oxidation; Rheumatoid arthritis; Synovitis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ANTIRHEUMATIC AGENT; ASCORBIC ACID; COLLAGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METRONIDAZOLE; MITOCHONDRIAL DNA; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; RETINOL; T LYMPHOCYTE ANTIGEN; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; APOPTOSIS; CELL METABOLISM; CLINICAL TRIAL; CYTOKINE PRODUCTION; ENZYME ACTIVITY; FENTON REACTION; GENE EXPRESSION; GENE MUTATION; HUMAN; HYPOXIA; LIPID PEROXIDATION; MOLECULAR INTERACTION; MOLECULAR MECHANICS; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PHAGOCYTE; PROTEIN DEGRADATION; PROTEIN FUNCTION; REGULATORY MECHANISM; REOXYGENATION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVITIS; VITAMIN SUPPLEMENTATION;

ANTIOXIDANTS; ARTHRITIS, RHEUMATOID; CELL HYPOXIA; CYTOKINES; DNA DAMAGE; GENE EXPRESSION REGULATION; HUMANS; LIPID PEROXIDATION; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; OXIDATION-REDUCTION; OXIDATIVE STRESS; OXYGEN; PHAGOCYTES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE; SYNOVITIS;

EID: 8544232149     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar1447     Document Type: Review

References (138)

1. Babior BM: Phagocytes and oxidative stress. Am J Med 2000, 109:33-44.
2. Lotz M: Neuropeptides, free radicals and nitric oxide. In Rheumatology. 3rd edition. Edited by Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH. Toronto: Mosby; 2003:135-146.
3. Olofsson P, Holmberg J, Tordsson J, Lu S, Akerstrom B, Holmdahl R: Positional identification of Ncf1 as a gene that regulates arthritis severity in rats. Nat Genet 2003, 33:25-32.
4. van de Loo FA, Bennink MB, Arntz OJ, Smeets RL, Lubberts E, Joosten LA, van Lent PL, Coenen-de Roo CJ, Cuzzocrea S, Segal BH, et al.: Deficiency of NADPH oxidase components p47phox and gp91phox caused granulomatous synovitis and increased connective tissue destruction in experimental arthritis models. Am J Pathol 2003, 163:1525-1537.
5. van der Veen RC, Dietlin TA, Hofman FM, Pen L, Segal BH, Holland SM: Superoxide prevents nitric oxide-mediated suppression of helper T lymphocytes: decreased autoimmune encephalomyelitis in nicotinamide adenine dinucleotide phosphate oxidase knockout mice. J Immunol 2000, 164:5177-5183.
6. Dhar SK, Lynn BC, Daosukho C, St Clair DK: Identification of nucleophosmin as an NF-κB co-activator for the induction of the human SOD2 gene. J Biol Chem 2004, 279:28209-28219.
7. Tan M, Li S, Swaroop M, Guan K, Oberley LW, Sun Y: Transcriptional activation of the human glutathione peroxidase promoter by p53. J Biol Chem 1999, 274:12061-12066.
8. Bierl C, Voetsch B, Jin RC, Handy DE, Loscalzo J: Determinants of human plasma glutathione peroxidase (GPx-3) expression. J Biol Chem 2004, 279:26839-26845.
9. Yamamoto M, Yang G, Hong C, Liu J, Holle E, Yu X, Wagner T, Vatner SF, Sadoshima J: Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. J Clin Invest 2003, 112:1395-1406.
10. Turoczi T, Chang VW, Engelman RM, Maulik N, Ho YS, Das DK: Thioredoxin redox signaling in the ischemic heart: an insight with transgenic mice overexpressing Trx1. J Mol Cell Cardiol 2003, 35:695-704.
11. Das DK: Thioredoxin regulation of ischemic preconditioning. Antioxid Redox Signal 2004, 6:405-412.
12. Maurice MM, Nakamura H, Gringhuis S, Okamoto T, Yoshida S, Kullmann F, Lechner S, van der Voort EA, Leow A, Versendaal J, Muller-Ladner U, Yodoi J, Tak PP, Breedveld FC, Verweij CL: Expression of the thioredoxin-thioredoxin reductase system in the inflamed joints of patients with rheumatoid arthritis. Arthritis Rheum 1999, 42: 430-2439.
13. Sowers M, Lachance L: Vitamins and arthritis. The roles of vitamins A, C, D, and E. Rheum Dis Clin North Am 1999, 25: 15-332.
14. Cerhan JR, Saag KG, Merlino LA, Mikuls TR, Criswell LA: Antioxidant micronutrients and risk of rheumatoid arthritis in a cohort of older women. Am J Epidemiol 2003, 157:345-354.
15. Heliovaara M, Knekt P, Aho K, Aaran RK, Alfthan G, Aromaa A: Serum antioxidants and risk of rheumatoid arthritis. Ann Rheum Dis 1994, 53:51-53.
16. Hagfors L, Leanderson P, Skoldstam L, Andersson J, Johansson G: Antioxidant intake, plasma antioxidants and oxidative stress in a randomized, controlled, parallel, Mediterranean dietary intervention study on patients with rheumatoid arthritis. Nutr J 2003, 2: .
17. Bae SC, Kim SJ, Sung MK: Inadequate antioxidant nutrient intake and altered plasma antioxidant status of rheumatoid arthritis patients. J Am Coll Nutr 2003, 22:311-315.
18. Paredes S, Girona J, Hurt-Camejo E, Vallve JC, Olive S, Heras M, Benito P, Masana L: Antioxidant vitamins and lipid peroxidation in patients with rheumatoid arthritis: association with inflammatory markers. J Rheumatol 2002, 29:2271-2277.
19. Mulherin DM, Thurnham DI, Situnayake RD: Glutathione reductase activity, riboflavin status, and disease activity in rheumatoid arthritis. Ann Rheum Dis 1996, 55:837-840.
20. Dabbagh AJ, Trenam CW, Morris CJ, Blake DR: Iron in joint inflammation. Ann Rheum Dis 1993, 52:67-73.
21. De Leo ME, Tranghese A, Passantino M, Mordente A, Lizzio MM, Galeotti T, Zoli A: Manganese superoxide dismutase, glutathione peroxidase, and total radical trapping antioxidant capacity in active rheumatoid arthritis. J Rheumatol 2002, 29: 2245-2246.
22. Taysi S, Polat F, Gul M, Sari RA, Bakan E: Lipid peroxidation, some extracellular antioxidants, and antioxidant enzymes in serum of patients with rheumatoid arthritis. Rheumatol Int 2002, 21:200-204.
23. Cimen MY, Cimen OB, Kacmaz M, Ozturk HS, Yorgancioglu R, Durak I: Oxidant/antioxidant status of the erythrocytes from patients with rheumatoid arthritis. Clin Rheumatol 2000, 19: 275-277.
24. Marklund SL, Bjelle A, Elmqvist LG: Superoxide dismutase isoenzymes of the synovial fluid in rheumatoid arthritis and in reactive arthritides. Ann Rheum Dis 1986, 45:847-851.
25. Ozturk HS, Cimen MY, Cimen OB, Kacmaz M, Durak I: Oxidant/antioxidant status of plasma samples from patients with rheumatoid arthritis. Rheumatol Int 1999, 19:35-37.
26. Henrotin YE, Bruckner P, Pujol JP: The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthritis Cartilage 2003, 11:747-755.
27. Halliwell B: Oxygen radicals, nitric oxide and human inflammatory joint disease. Ann Rheum Dis 1995, 54: 05-510.
28. Tak PP, Zvaifler NJ, Green DR, Firestein GS: Rheumatoid arthritis and p53: how oxidative stress might alter the course of inflammatory diseases. Immunol Today 2000, 21:78-82.
29. Grootveld M, Henderson EB, Farrell A, Blake DR, Parkes HG, Haycock P: Oxidative damage to hyaluronate and glucose in synovial fluid during exercise of the inflamed rheumatoid joint. Detection of abnormal low-molecular-mass metabolites by proton-n.m.r. spectroscopy. Biochem J 1991, 273:459-467.
30. Rowley D, Gutteridge JM, Blake D, Farr M, Halliwell B: Lipid peroxidation in rheumatoid arthritis: thiobarbituric acid-reactive material and catalytic iron salts in synovial fluid from rheumatoid patients. Clin Sci (Lond) 1984, 66:691-695.
31. Taysi S, Polat F, Gul M, Sari RA, Bakan E: Lipid peroxidation, some extracellular antioxidants, and antioxidant enzymes in serum of patients with rheumatoid arthritis. Rheumatol Int 2002, 21:200-204.
32. Dai L, Lamb DJ, Leake DS, Kus ML, Jones HW, Morris CJ, Winyard PG: Evidence for oxidised low density lipoprotein in synovial fluid from rheumatoid arthritis patients. Free Radic Res 2000, 32:479-486.
33. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R: Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 2003, 329:23-38.
34. Cemerski S, van Meerwijk JP, Romagnoli P: Oxidative-stress-induced T lymphocyte hyporesponsiveness is caused by structural modification rather than proteasomal degradation of crucial TCR signaling molecules. Eur J Immunol 2003, 33: 2178-2185.
35. Bandt MD, Grossin M, Driss F, Pincemail J, Babin-Chevaye C, Pasquier C: Vitamin E uncouples joint destruction and clinical inflammation in a transgenic mouse model of rheumatoid arthritis. Arthritis Rheum 2002, 46:522-532.
36. Cuzzocrea S, McDonald MC, Mota-Filipe H, Mazzon E, Costantino G, Britti D, Mazzullo G, Caputi AP, Thiemermann C: Beneficial effects of tempol, a membrane-permeable radical scavenger, in a rodent model of collagen-induced arthritis. Arthritis Rheum 2000, 43: 20-328.
37. Venkatraman JT, Chu WC: Effects of dietary omega-3 and omega-6 lipids and vitamin E on serum cytokines, lipid mediators and anti-DNA antibodies in a mouse model for rheumatoid arthritis. J Am Coll Nutr 1999, 18:602-613.
38. Clancy RM, Rediske J, Tang X, Nijher N, Frenkel S, Philips M, Abramson SB: Outside-in signaling in the chondrocyte. Nitric oxide disrupts fibronectin-induced assembly of a subplasmalemmal actin/rho A/focal adhesion kinase signaling complex. J Clin Invest 1997, 100:1789-1796.
39. Rees MD, Hawkins CL, Davies MJ: Hypochlorite-mediated fragmentation of hyaluronan, chondroitin sulfates, and related N-acetyl glycosamines: evidence for chloramide intermediates, free radical transfer reactions, and site-specific fragmentation. J Am Chem Soc 2003, 125:13719-13733.
40. Rees MID, Hawkins CL, Davies MJ: Hypochlorite and superoxide radicals can act synergistically to induce fragmentation of hyaluronan and chondroitin sulfates. Biochem J 2004, 381: 75-184.
41. Panasyuk A, Frati E, Ribault D, Mitrovic D: Effect of reactive oxygen species on the biosynthesis and structure of newly synthesized proteoglycans. Free Radic Biol Med 1994, 16: 57-167.
42. Newkirk MM, LePage K, Niwa T, Rubin L: Advanced glycation endproducts (AGE) on IgG, a target for circulating antibodies in North American Indians with rheumatoid arthritis (RA). Cell Mol Biol (Noisy-le-grand) 1998, 44:1129-1138.
43. Newkirk MM, Goldbach-Mansky R, Lee J, Hoxworth J, McCoy A, Yarboro C, Klippel J, El Gabalawy HS: Advanced glycation end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis. Arthritis Res Ther 2003, 5: R82-R90.
44. Bashir S, Harris G, Denman MA, Blake DR, Winyard PG: Oxidative DNA damage and cellular sensitivity to oxidative stress in human autoimmune diseases. Ann Rheum Dis 1993, 52:659-666.
45. Hajizadeh S, DeGroot J, TeKoppele JM, Tarkowski A, Collins LV: Extracellular mitochondrial DNA and oxidatively damaged DNA in synovial fluid of patients with rheumatoid arthritis. Arthritis Res Ther 2003, 5:R234-R240.
46. Lee SH, Chang DK, Goel A, Boland CR, Bugbee W, Boyle DL, Firestein GS: Microsatellite instability and suppressed DNA repair enzyme expression in rheumatoid arthritis. J Immunol 2-15-2003, 170:2214-2220.
47. Forrester K, Ambs S, Lupold SE, Kapust RB, Spillare EA, Weinberg WC, Felley-Bosco E, Wang XW, Geller DA, Tzeng E, et al.: Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci USA 1996, 93:2442-2447.
48. Firestein GS, Echeverri F, Yeo M, Zvaifler NJ, Green DR: Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 1997, 94: 0895-10900.
49. Inazuka M, Tahira T, Horiuchi T, Harashima S, Sawabe T, Kondo M, Miyahara H, Hayashi K: Analysis of p53 tumour suppressor gene somatic mutations in rheumatoid arthritis synovium. Rheumatology (Oxford) 2000, 39:262-266.
50. Yamanishi Y, Boyle DL, Rosengren S, Green DR, Zvaifler NJ, Firestein GS: Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 2002, 99: 10025-10030.
51. Yakes FM, Van Houten B: Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci USA 1997, 94: 14-519.
52. Collins LV, Hajizadeh S, Holme E, Jonsson IM, Tarkowski A: Endogenously oxidized mitochondrial DNA induces in vivo and in vitro inflammatory responses. J Leukoc Biol 2004, 75:995-1000.
53. Tiku ML, Shah R, Allison GT: Evidence linking chondrocyte lipid peroxidation to cartilage matrix protein degradation. Possible role in cartilage aging and the pathogenesis of osteoarthritis. J Biol Chem 2000, 275:20069-20076.
54. Lusis AJ: Atherosclerosis. Nature 2000, 407: 33-241.
55. del Rincon I, Escalante A: Atherosclerotic cardiovascular disease in rheumatoid arthritis. Curr Rheumatol Rep 2003, 5: 78-286.
56. Sattar N, McCarey DW, Capell H, McInnes IB: Explaining how 'high-grade' systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003, 108:2957-2963.
57. Dai L, Lamb DJ, Leake DS, Kus ML, Jones HW, Morris CJ, Winyard PG: Evidence for oxidised low density lipoprotein in synovial fluid from rheumatoid arthritis patients. Free Radic Res 2000, 32:479-486.
58. Winyard PG, Tatzber F, Esterbauer H, Kus ML, Blake DR, Morris CJ: Presence of foam cells containing oxidised low density lipoprotein in the synovial membrane from patients with rheumatoid arthritis. Ann Rheum Dis 1993, 52:677-680.
59. Treuhaft PS, McCarty DJ: Synovial fluid pH, lactate, oxygen and carbon dioxide partial pressure in various joint diseases. Arthritis Rheum 1971, 14:475-484.
60. Lund-Olesen K: Oxygen tension in synovial fluids. Arthritis Rheum 1970, 13:769-776.
61. Naughton D, Whelan M, Smith EC, Williams R, Blake DR, Grootveld M: An investigation of the abnormal metabolic status of synovial fluid from patients with rheumatoid arthritis by high field proton nuclear magnetic resonance spectroscopy. FEBS Lett 1993, 317:135-138.
62. Naughton DP, Haywood R, Blake DR, Edmonds S, Hawkes GE, Grootveld M: A comparative evaluation of the metabolic profiles of normal and inflammatory knee-joint synovial fluids by high resolution proton NMR spectroscopy. FEBS Lett 1993, 332:221-225.
63. Taylor P, Miotla JM, Etherington P, Winlove P, Young Y, Paleolog E, Maini RN: VEGF release is associated with hypoxia in inflammatory arthritis [abstract]. Arthritis Rheum 2000, 43 Suppl 9:S296.
64. Ellis GA, Edmonds SE, Gaffney K, Williams RB: Synovial tissue oxygenation profile in inflamed and non-inflamed knee joints [abstract]. Br J Rheumatol 1994, 33 Suppl 1:172
65. Miotla J, Maciewicz R, Kendrew J, Feldmann M, Paleolog E: Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest 2000, 80:1195-1205.
66. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, et al.: Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998, 394:485-490.
67. Marx J: Cell biology. How cells endure low oxygen. Science 2004, 303:1454-1456.
68. 2, and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 2001, 107:1-3.
69. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG: Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000, 2:423-427.
70. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH: Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000, 275:25733-25741.
71. 2-regulated gene expression. FASEB J 2002, 16:1151-1162.
72. Distler JH, Wenger RH, Gassmann M, Kurowska M, Hirth A, Gay S, Distler O: Physiologic responses to hypoxia and implications for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 2004, 50:10-23.
73. Matsumoto I, Staub A, Benoist C, Mathis D: Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 1999, 286:1732-1735.
74. Schaller M, Burton DR, Ditzel HJ: Autoantibodies to GPI in rheumatoid arthritis: linkage between an animal model and human disease. Nat Immunol 2001, 2:746-753.
75. Matsumoto I, Lee DM, Goldbach-Mansky R, Sumida T, Hitchon CA, Schur PH, Anderson RJ, Coblyn JS, Weinblatt ME, Brenner M, et al.: Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders. Arthritis Rheum 2003, 48:944-954.
76. Naughton DP: Hypoxia-induced upregulation of the glycolytic enzyme glucose-6-phosphate isomerase perpetuates rheumatoid arthritis. Med Hypotheses 2003, 60:332-334.
77. Cramer T, Yamanishi Y, Clausen BE, Forster I, Pawlinski R, Mackman N, Haase VH, Jaenisch R, Corr M, Nizet V, et al.: HIF-1α is essential for myeloid cell-mediated inflammation. Cell 2003, 112:645-657.
78. Michiels C, Minet E, Mottet D, Raes M: Regulation of gene expression by oxygen: NF-κB and HIF-1, two extremes. Free Radic Biol Med 2002, 33:1231-1242.
79. Huang LE, Willmore WG, Gu J, Goldberg MA, Bunn HF: Inhibition of hypoxia-inducible factor 1 activation by carbon monoxide and nitric oxide. Implications for oxygen sensing and signaling. J Biol Chem 1999, 274:9038-9044.
80. 2 sensing. J Biol Chem 2000, 275: 5130-25138.
81. Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, Schumacker PT: Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci USA 1998, 95:11715-11720.
82. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL: Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002, 277:38205-38211.
83. Jung YJ, Isaacs JS, Lee S, Trepel J, Neckers L: IL-1β-mediated up-regulation of HIF-1α via an NFκB /COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 2003, 17:2115-2117.
84. Stiehl DP, Jelkmann W, Wenger RH, Hellwig-Burgel T: Normoxic induction of the hypoxia-inducible factor 1α by insulin and interleukin-1β involves the phosphatidylinositol 3-kinase pathway. FEBS Lett 2002, 512:157-162.
85. Zhou J, Schmid T, Brune B: Tumor necrosis factor-alpha causes accumulation of a ubiquitinated form of hypoxia inducible factor-1α through a nuclear factor-κB-dependent pathway. Mol Biol Cell 2003, 14:2216-2225.
86. Jung Y, Isaacs JS, Lee S, Trepel J, Liu ZG, Neckers L: Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor κB activation. Biochem J 2003, 370:1011-1017.
87. Thornton RD, Lane P, Borghaei RC, Pease EA, Caro J, Mochan E: Interleukin 1 induces hypoxia-inducible factor 1 in human gingival and synovial fibroblasts. Biochem J 2000, 350:307-312.
88. Minet E, Arnould T, Michel G, Roland I, Mottet D, Raes M, Remacle J, Michiels C: ERK activation upon hypoxia: involvement in HIF-1 activation. FEBS Lett 2000, 468:53-58.
89. Kasuno K, Takabuchi S, Fukuda K, Kizaka-Kondoh S, Yodoi J, Adachi T, Semenza GL, Hirota K: Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphaticlylinositol 3-kinase signaling. J Biol Chem 2004, 279:2550-2558.
90. Giatromanolaki A, Sivridis E, Maltezos E, Athanassou N, Papazoglou D, Gatter KC, Harris AL, Koukourakis MI: Upregulated hypoxia inducible factor-1α and -2α pathway in rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 2003, 5:R193-R201.
91. Hitchon CA, Wong K, Ma G, Reed J, Lyttle D, El Gabalawy H: Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. Arthritis Rheum 2002, 46:2587-2597.
92. Hollander AP, Corke KP, Freemont AJ, Lewis CE: Expression of hypoxia-inducible factor 1α by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum 2001, 44:1540-1544.
93. Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH, Gassmann M: Induction of HIF-1α in response to hypoxia is instantaneous. FASEB J 2001, 15:1312-1314.
94. Wauke K, Nagashima M, Ishiwata T, Asano G, Yoshino S: Expression and localization of vascular endothelial growth factor-C in rheumatoid arthritis synovial tissue. J Rheumatol 2002, 29: 4-38.
95. Kasama T, Shiozawa F, Kobayashi K, Yajima N, Hanyuda M, Takeuchi HT, Mori Y, Negishi M, Ide H, Adachi M: Vascular endothelial growth factor expression by activated synovial leukocytes in rheumatoid arthritis: critical involvement of the interaction with synovial fibroblasts. Arthritis Rheum 2001, 44: 2512-2524.
96. Ballara S, Taylor PC, Reusch P, Marme D, Feldmann M, Maini RN, Paleolog EM: Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 2001, 44:2055-2064.
97. Pufe T, Petersen W, Tillmann B, Mentlein R: Splice variants VEGF121 and VEGF165 of the angiogenic peptide vascular endothelial cell growth factor are expressed in the synovial tissue of patients with rheumatoid arthritis. J Rheumatol 2001, 28: 482-1485.
98. Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, Jackman RW, Senger DR, Dvorak HF, Brown LF: Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994, 180:341-346.
99. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN: Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998, 41:1258-1265.
100. Berse B, Hunt JA, Diegel RJ, Morganelli P, Yeo K, Brown F, Fava RA: Hypoxia augments cytokine (transforming growth factor-β (TGF-β) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin Exp Immunol 1999, 115: 76-182.
101. Sanchez-Elsner T, Botella LM, Velasco B, Corbi A, Attisano L, Bernabeu C: Synergistic cooperation between hypoxia and transforming growth factor-β pathways on human vascular endothelial growth factor gene expression. J Biol Chem 2001, 276:38527-38535.
102. Takahara K, Iioka T, Furukawa K, Uchida T, Nakashima M, Tsukazaki T, Shindo H: Autocrine/paracrine role of the angiopoietin-1 and -2/Tie2 system in cell proliferation and chemotaxis of cultured fibroblastic synoviocytes in rheumatoid arthritis. Hum Pathol 2004, 35:150-158.
103. Fearon U, Griosios K, Fraser A, Reece R, Emery P, Jones PF, Veale DJ: Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol 2003, 30:260-268.
104. DeBusk LM, Chen Y, Nishishita T, Chen J, Thomas JW, Lin PC: Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor alpha-induced angiogenesis in rheumatoid arthritis. Arthritis Rheum 2003, 48:2461-2471.
105. Gravallese EM, Pettit AR, Lee R, Madore R, Manning C, Tsay A, Gaspar J, Goldring MB, Goldring SR, Oettgen P: Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor alpha. Ann Rheum Dis 2003, 62:100-107.
106. Stevens CR, Blake DR, Merry P, Revell PA, Levick JR: A comparative study by morphometry of the microvasculature in normal and rheumatoid synovium. Arthritis Rheum 1991, 34: 1508-1513.
107. Levick JR: Hypoxia and acidosis in chronic inflammatory arthritis; relation to vascular supply and dynamic effusion pressure. J Rheumatol 1990, 17:579-582.
108. James MJ, Cleland LG, Rofe AM, Leslie AL: Intraarticular pressure and the relationship between synovial perfusion and metabolic demand. J Rheumatol 1990, 17:521-527.
109. Bonizzi G, Piette J, Merville MP, Bours V: Cell type-specific role for reactive oxygen species in nuclear factor-κB activation by interieukin-1. Biochem Pharmacol 2000, 59: -11.
110. Bonizzi G, Piette J, Schoonbroodt S, Greimers R, Havard L, Merville MP, Bours V: Reactive oxygen intermediate-dependent NF-κB activation by interleukin-1β requires 5-lipoxygenase or NADPH oxidase activity. Mol Cell Biol 1999, 19:1950-1960.
111. D'Angio CT, Finkelstein JN: Oxygen regulation of gene expression: a study in opposites. Mol Genet Metab 2000, 71: 71-380.
112. Han MK, Kim JS, Park BH, Kim JR, Hwang BY, Lee HY, Song EK, Yoo WH: NF-κB-dependent lymphocyte hyperadhesiveness to synovial fibroblasts by hypoxia and reoxygenation: potential role in rheumatoid arthritis. J Leukoc Biol 2003, 73:525-529.
113. Uchiyama T, Engelman RM, Maulik N, Das DK: Role of Akt signaling in mitochondrial survival pathway triggered by hypoxic preconditioning. Circulation 2004, 109:3042-3049.
114. Jones NM, Bergeron M: Hypoxia-induced schemic tolerance in neonatal rat brain involves enhanced ERK1/2 signaling. J Neurochem 2004, 89:157-167.
115. Marxsen JH, Stengel P, Doege K, Heikkinen P, Jokilehto T, Wagner T, Jelkmann W, Jaakkola P, Metzen E: Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-α-prolyl-4-hydroxylases. Biochem J. 2004, 381: 61-767.
116. Haqqi TM, Anthony DD, Gupta S, Ahmad N, Lee MS, Kumar GK, Mukhtar H: Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea. Proc Natl Acad Sci USA 1999, 96:4524-4529.
117. Singh R, Ahmed S, Islam N, Goldberg VM, Haqqi TM: Epigallocatechin-3-gallate inhibits interieukin-1β-induced expression of nitric oxide synthase and production of nitric oxide in human chondrocytes: suppression of nuclear factor κB activation by degradation of the inhibitor of nuclear factor κB. Arthritis Rheum 2002, 46:2079-2086.
118. Ahmed S, Wang N, Lalonde M, Goldberg VM, Haqqi TM: Green tea polyphenol epigallocatechin-3-gallate (EGCG) differentially inhibits interieukin-1β-induced expression of matrix metalloproteinase-1 and -13 in human chondrocytes. J Pharmacol Exp Ther 2004, 308: 67-773.
119. Ahmed S, Rahman A, Hasnain A, Lalonde M, Goldberg VM, Haqqi TM: Green tea polyphenol epigallocatechin-3-gallate inhibits the IL-1β-induced activity and expression of cyclooxygenase-2 and nitric oxide synthase-2 in human chondrocytes. Free Radic Biol Med 2002, 33:1097-1105.
120. Skoldstam L, Hagfors L, Johansson G: An experimental study of a Mediterranean diet intervention for patients with rheumatoid arthritis. Ann Rheum Dis 2003, 62:208-214.
121. Jaswal S, Mehta HC, Sood AK, Kaur J: Antioxidant status in rheumatoid arthritis and role of antioxidant therapy. Clin Chim Acta 2003, 338:123-129.
122. Edmonds SE, Winyard PG, Guo R, Kidd B, Merry P, Langrish-Smith A, Hansen C, Ramm S, Blake DR: Putative analgesic activity of repeated oral doses of vitamin E in the treatment of rheumatoid arthritis. Results of a prospective placebo controlled double blind trial. Ann Rheum Dis 1997, 56:649-655.
123. Koch AE: Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis 2003, 62 Suppl 2:ii6O-67.
124. Trabold O, Wagner S, Wicke C, Scheuenstuhl H, Hussain MZ, Rosen N, Seremetiev A, Becker HD, Hunt TK: Lactate and oxygen constitute a fundamental regulatory mechanism in wound healing. Wound Repair Regen 2003, 11:504-509.
125. Albina JE, Reichner JS: Oxygen and the regulation of gene expression in wounds. Wound Repair Regen 2003, 11:445-451.
126. Haroon ZA, Raleigh JA, Greenberg CS, Dewhirst MW: Early wound healing exhibits cytokine surge without evidence of hypoxia. Ann Surg 2000, 231:137-147.
127. Ozawa K, Kondo T, Hori O, Kitao Y, Stern DM, Eisenmenger W, Ogawa S, Ohshima T: Expression of the oxygen-regulated protein ORP150 accelerates wound healing by modulating intracellular VEGF transport. J Clin Invest 2001, 108:41-50.
128. Scheid A, Wenger RH, Christina H, Camenisch I, Ferenc A, Stauffer UG, Gassmann M, Meuli M: Hypoxia-regulated gene expression in fetal wound regeneration and adult wound repair. Pediatr Surg Int 2000, 16:232-236.
129. Albina JE, Mastrofrancesco B, Vessella JA, Louis CA, Henry WL Jr, Reichner JS: HIF-1 expression in healing wounds: HIF-1α induction in primary inflammatory cells by TNF-α. Am J Physiol Cell Physiol 2001, 281:C1971-C1977.
130. Giaccia A, Siim BG, Johnson RS: HIF-1 as a target for drug development. Nat Rev Drug Discov 2003, 2:803-811.
131. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732.
132. Pufe T, Lemke A, Kurz B, Petersen W, Tillmann B, Grodzinsky AJ, Mentlein R: Mechanical overload induces VEGF in cartilage discs via hypoxia-inducible factor. Am J Pathol 2004, 164: 85-192.
133. Stokes DG, Liu G, Coimbra IB, Piera-Velazquez S, Crowl RM, Jimenez SA: Assessment of the gene expression profile of differentiated and dedifferentiated human fetal chondrocytes by microarray analysis. Arthritis Rheum 2002, 46:404-419.
134. Coimbra IB, Jimenez SA, Hawkins DF, Piera-Velazquez S, Stokes DG: Hypoxia inducible factor-1α expression in human normal and osteoarthritic chondrocytes. Osteoarthritis Cartilage 2004, 12:336-345.
135. Rajpurohit R, Koch CJ, Tao Z, Teixeira CM, Shapiro IM: Adaptation of chondrocytes to low oxygen tension: relationship between hypoxia and cellular metabolism. J Cell Physiol 1996, 168: 24-432.
136. Schipani E, Ryan HE, Didrickson S, Kobayashi T, Knight M, Johnson RS: Hypoxia in cartilage: HIF-1α is essential for chondrocyte growth arrest and survival. Genes Dev 2001, 15:2865-2876.
137. Bodamyali T, Stevens CR, Billingham ME, Ohta S, Blake DR: Influence of hypoxia in inflammatory synovitis. Ann Rheum Dis 1998, 57:703-710.
138. Marshall DA, Hunter JA, Capell HA: Double blind, placebo controlled study of metronidazole as a disease modifying agent in the treatment of rheumatoid arthritis. Ann Rheum Dis 1992, 51: 58-760.